Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) — MIBS  

Irritable Bowel Syndrome With Diarrhoea Clinical Trial

Official title: Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).

Status Completed

Clinical Trial Summary

The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea.

The investigators will therefore evaluate symptoms (primarily bowel frequency) and markers reflecting mast cell activation and small bowel tone.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diarrhea
• Irritable Bowel Syndrome
• Irritable Bowel Syndrome With Diarrhoea
• Syndrome

• NCT number: NCT01316718
• Study type: Interventional
• Source: University of Nottingham
• Status: Completed
• Phase: Phase 4
• Start date: March 2011
• Completion date: September 2013